Shanghai-based Active Technology has secured a landmark RMB 330 million in an angel funding round, setting a new record for the brain-computer interface sector in China. This significant investment underscores the growing confidence in invasive BCI technology and its potential to address complex neurological conditions. The funding will propel the company's mission to translate its advanced research into tangible clinical applications for patients.
A New Benchmark in BCI Investment
The record-setting round was led by prominent investor Zhongke Chuangxing, with substantial participation from a consortium including Lenovo Star, 9 Capital, and Daotong Investment. This diverse group of backers highlights the broad appeal of Active Technology's vision and technological prowess within the investment community. The capital injection is earmarked for strategic growth initiatives to solidify the company's market position.
Active Technology will allocate the new funds towards several key areas critical for its development and expansion. The company plans to enhance its facilities, upgrade its research and production equipment, and significantly expand its team of experts. These investments are designed to accelerate the progression of its products through crucial clinical trial phases and towards commercialization.
Pioneering Invasive BCI Technology
Founded earlier this year, Active Technology specializes in the development of advanced invasive BCI systems. The company's product pipeline includes solutions for motor, visual, and emotional neural interfaces, demonstrating a comprehensive approach to the field. Their core strategy involves an integrated, full-stack development process covering everything from flexible electrodes to proprietary decoding algorithms.
A key product in their portfolio is the "Tianshu" motor BCI system, designed to restore motor and language functions for individuals affected by paralysis. This system is aimed at patients with conditions such as stroke, spinal cord injury, and ALS. The technology represents a significant step forward in providing functional recovery and improving quality of life for these patients.
Accelerating Towards Clinical Application
The company is poised to begin clinical trials for its "Tianshu" system, which notably features a 1024-channel interface. This high channel count allows for greater brain signal throughput and more precise information decoding, establishing a robust hardware foundation. Active Technology aims to be the first enterprise in China to initiate clinical trials with such a high-density invasive BCI system.
To support its ambitious goals, the company has already established a 2,500-square-meter facility that combines office space with a GMP-certified workshop. Looking ahead, Active Technology plans to construct a new headquarters spanning over 10,000 square meters by the end of 2026. This expansion will accommodate a growing team and advanced manufacturing capabilities, including a micro-nano processing platform.
A Thriving and Competitive Landscape
This funding arrives amidst a significant acceleration in China's BCI industry, which saw a surge in investment during the first half of the year. The sector's growth is bolstered by supportive national policies and increasing progress in clinical applications across the board. Experts anticipate that investor interest will remain high as the technology moves closer to widespread industrialization.
Investors are increasingly focusing on companies with demonstrable technological strength and a clear path to commercialization. Key areas of interest include medical rehabilitation, the development of core upstream hardware like neural signal chips, and advanced AI-driven decoding algorithms. This discerning approach is expected to intensify competition and drive innovation within the rapidly evolving BCI landscape.
Active Technology's record-breaking angel round is a pivotal moment for both the company and China's burgeoning BCI sector. The substantial investment not only validates the company's innovative approach but also signals the immense potential of neurotechnology to create transformative medical solutions. As the company advances its clinical trials and expands its operations, it is well-positioned to become a key player in the global BCI market.